Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing. (7th September 2022)

• Record Type: Journal Article
• Authors: Johnson, Shelsey W.; Finlay, Lauren; Mathai, Stephen C.; Goldstein, Ronald H.; Maron, Bradley A.
• Is Part Of: Pulmonary circulation. Volume 12:Number 3(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-09-07
• Subjects: Group 3 pulmonary hypertension -- inhaled treprostinil -- interstitial lung disease -- pulmonary hypertension; Pulmonary circulation -- Periodicals; Pulmonary circulation; Electronic journals -- Sciences; Periodicals; 616.24005
• DOI: 10.1002/pul2.12126
• Languages: English
• ISSNs: 2045-8932

Abstract

Abstract: Inhaled treprostinil was approved recently for interstitial lung disease‐pulmonary hypertension; however, efficacy in "real‐world" populations is not known. We designed a protocol and report our experience evaluating 10 patients referred for therapy. Misdiagnosis at presentation was common; ultimately, three patients (30%) were prescribed drug. This protocol offers an opportunity to standardize longitudinal assessment of inhaled treprostinil in clinical practice.